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Background: The importance of mitochondrial DNA (mtDNA) polymorphism in the prediction of type 2 diabetes
(T2D) in men and women is not well understood. We questioned whether mtDNA polymorphism, mitochondrial
functions, age and gender influenced the occurrence of T2D with or without ischemic stroke (IS).
Methods: We first designed a matched case–control study of 373 T2D patients and 327 healthy unrelated individuals
without history of IS. MtDNA haplogroups were determined on all participants using sequencing of the control region
and relevant SNPs from the coding region. Mitochondria functional tests, systemic biochemical measurements and
complete genomic mtDNA sequencing were further determined on 239 participants (73 healthy controls, 33 T2D with
IS, 70 T2D only and 63 IS patients without T2D).
Results: MtDNA haplogroups B4a1a, and E2b1 showed significant association with T2D (P <0.05), and haplogroup
D4 indicated resistance (P <0.05). Mitochondrial and systemic functional tests showed significantly less variance
within groups bearing the same mtDNA haplotypes. There was a pronounced male excess among all T2D patients
and prevalence of IS was seen only in the older population. Finally, nucleotide variant np 15746, a determinant of
haplogroup G3 seen in Japanese and of B4a1a prevalent in Taiwanese was associated with T2D in both populations.
Conclusions: Men appeared more susceptible to T2D than women. Although the significant association of B4a1a
and E2b1 with T2D ceased when corrected for multiple testings, these haplogroups are seen only among Taiwan
Aborigines, Southeast Asian and the Pacific Ocean islanders where T2D is predominant. The data further suggested that
physiological and biochemical measurements were influenced by the mtDNA genetic profile of the individual. More
understanding of the function of the mitochondrion in the development of T2D might indicate ways of influencing the
early course of the disease.Background
Mitochondrial DNA (mtDNA) codes for thirteen protein
subunits of the mitochondria electron transport chain
(ETC.), two ribosomal RNAs and twenty-two transfer
RNAs that are essential in the mitochondrial protein
synthesis. Although the complete mtDNA genome size
is very small compared to nuclear DNA, its high muta-
tion rate (28.2 to 42.5 greater than nuclear DNA) sug-
gests that the role of mtDNA holds an important and
active role in human evolution [1].* Correspondence: marilin@ms2.mmh.org.tw
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unless otherwise stated.At the end of the Paleolithic period, the ancient con-
tinent of Sundaland was being covered with the rise of
sea levels and separated Taiwan and Western Island
Southeast Asia (ISEA) from the Asian Continent [2].
Relocation and ensuing long isolation of its peoples
resulted into the emergence of several mtDNA sub-
haplogroups (HG) specific to Taiwan, ISEA and Oceania
such as B4a1a and E and rarely seen in continental Asia
[2,3]. The weather in Taiwan, ISEA and Oceania is
generally hot, humid. This climate not only provides
an ideal environment for infective microorganisms to
develop, but must have also acted on the populations. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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effect of drift have lead to the expansion of mtDNA pro-
files unique to the Austronesian speakers of Taiwan and
ISEA [4,5].
While the economic status in Taiwan and ISEA after
World War II allowed for the introduction of antibiotics,
a significant decrease in infective diseases and a rapid
improvement of hygiene, the Western type of food and a
sedentary life style greatly contributed to obesity, and
prevalence of type 2 Diabetes (T2D). The number of
people with T2D in the world is close to 240 million,
with East Asians being the most affected and their
number expected to continue increasing if no effective
preventive steps are taken. Interestingly, it has also been
hypothesized that while insulin resistance favor T2D, it
may have also provided a more efficient way to use
energy to individuals in their new environment and
therefore a more efficient way to fight infection [6]. It
was later reported that the presence of mtDNA nucleo-
tide position (np) 15746 in Japanese and Korean people
[7-9] may be associated with T2D (or T2D with Ischemic
Stroke (T2DIS)). Since the mtDNA profile of the Japa-
nese is significantly different to the Taiwanese we aimed
at determining whether np 15746 was actually an inher-
ited ancestral trait associated to T2D, or the recurrence
of a mutation occurring in distinct mtDNA haplogroups
associated to T2D in different populations. Further, we
analyzed extensively the relationship between T2D and
control groups, their mtDNA polymorphism and their
mitochondria biological functions in Southern Taiwan.
Methods
Unrelated individuals (N = 808) over 45 years old from
the Mackay Memorial Hospital Taitung branch in south-
eastern Taiwan were recruited for this study. T2D is
usually associated with vascular complications (i.e. Ische-
mic stroke, myocardial-infraction, diabetic retinopathy,
nephropathy, small-vessel disease, large-artery atheroscler-
osis, etc.). A substantial proportion of T2D cases in our
sampling had also history of ischemic stroke (17.43%) and
were included in the analysis and Ischemic stroke patients
with no T2D history were later recruited for comparison.
Finally, the data set comprised 327 unrelated healthy
individuals (controls), 308 patients with T2D only
(T2Donly), 65 patients with T2D and history of ischemic
stroke (T2DIS), and 108 patients with IS only (ISonly). Indi-
cation on overnight fasting glucose, glycohemoglobin level
(HbA1c), kidney function, and medication records of cases
and control groups are listed in Additional file 1: Table S1.
All individuals provided their name, birthday, parent
ethnic affiliation, filled an epidemiological questionnaire
and gave informed consent to participate in the study. The
project was approved by the ethics committee of Mackay
Memorial Hospital, Taiwan.The following measurements and tests were conducted
at the Mackay Memorial Hospital Taitung branch using
standard techniques:
Individual’s physical outlook: height, weight, body mass
index (BMI), waist circumference.
Physiological measurements: systolic blood pressure,
diastolic blood pressure.
Blood biochemistry measurements: Overnight fasting
glucose, High Density Lipoprotein (HDL), Low Density
Lipoprotein (LDL), total cholesterol (TC), triglyceride,
uric acid, creatinine.
MtDNA sequencing
To analyze the polymorphism of mtDNA, DNA was
extracted from 500 μl of buffy coat from each blood
sample using the QIAmp DNA kit (QIAmp® DNA Blood
Mini kit from Qiagen inc. Taiwan). For mtDNA typing,
control region HVS-1, nucleotide positions (np) of coding
region fragments 8000 to 9000 and 9800 to 10900 were
sequenced using a method previously publications de-
scribed [3,10]. Complete mtDNA genome sequencing
was carried out on a total of 239 individuals (73 con-
trols, 70 T2Donly, 33 T2DIS, and 63 ISonly). Briefly, 24
fragments of mtDNA were amplified and sequenced in
both directions [11]. Haplogroup assignments were
done according to the “phylotree” criterion (www.phylo-
tree.org) using combinations of the HVS-1 sequence,
partial sequencing of the coding region, and other rele-
vant diagnostic variants. Each individual were assigned to
an ethnic group (either Taiwan non-Aborigine or Taiwan
Aborigine) according to the epidemiological questionnaire
which was filled at the time of blood sample collection.
Mtochondrial functional study
Under inflammation, cellular mitochondria develop mem-
brane hyperpolarization. These morphological changes are
also seen in the mononuclear cells of T2D patients [12].
Venous ACD blood collection in BD Vacutainer® (Becton
Dickinson, USA) and stored at 4°C for less than 24 hours
was found to be the best condition to transport specimens
to Taipei (350 km) for measurements of mitochondrial
functions and antioxidant capacities of the mononuclear
cells.
Isolation of mononuclear cells from peripheral blood
After centrifugation of the venous blood at 3000 g for
10 min, the buffy coat (2 mls) was diluted with an equal
volume of phosphate buffered saline solution (PBS),
layered over 2 ml Ficoll-Paque PLUS (GE Healthcare
Bio-Sciences AB, Sweden) and centrifuged at 2000 g for
20 min to separate mononuclear cells from polymor-
phonuclear neutrophils. The mononuclear cells were
removed and washed twice with PBS, and suspended in
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bility of all mononuclear cells, measured by trypan blue
dye exclusion, was greater than 95%. Due to the small vol-
ume collected and the large number of clinical measure-
ments performed for each participant in the study, test
were done without replication. Instead, an internal work-
ing standard was introduced with each set of experiment.
Except for the test of mtDNA copy number, Coefficient of
Variation (CV) shown in Additional file 2: Table S2 are
inter-assay CV.
Measurement of ATP levels in mononuclear cells
Intracellular ATP levels were determined using the Bio-
luminescent Somatic Cell Assay Kit (Sigma-Aldrich,
USA) according to the manufacturer’s instructions.
Measurement of hydrogen peroxide production (DCF)
and lipid-peroxidation in human mononuclear cells
Intracellular hydrogen peroxide and lipid-peroxidation levels
were measured using fluorescent dye 2′, 7′-dichlorodihy-
drofluorescein diacetate (DCF, Sigma-Aldrich, USA) and
C11-BODIPY581/591 (Molecular Probes, the Netherlands)
respectively. Both fluorescence measurement of DCF at
wavelengths 488/520 nm and C11-BODIPY581/591 measured
by simultaneous acquisition of the green (520 nm) and red
signal (695 nm) were obtained by flow cytometry (Becton
Dickinson, USA).
Flow cytometric determination of mitochondrial
membrane potential (DiOC)
Mitochondrial membrane potential was measured using
3,3′-diethyloxacarbocyanine iodide [DiOC2(3)] (Molecular
Probe, The Netherlands) labeled cells by flow cytometry at
488/520 nm wavelengths.
Measurement of superoxide dismutase (SOD) and
catalase activity in human mononuclear cells
Mononuclear cells were suspended in NEP buffer
(150 mM NaCl, 0.5 mM EDTA, 0.1 M LHPO4 buffer and
1% Triton X-100, pH 7.5) containing protease inhibitors
(Roche Diagnostics, USA). Cell suspension was incubated
on ice for 30 minutes at 4°C and the supernatant collected
for measurement of enzyme activity. SOD activity was
performed using the superoxide dismutase assay kit
(Cayman Chemical, USA) according to the manufac-
turer’s instruction and catalase activity was determined
by monitoring the rate of decomposition of hydrogen
peroxide from the decrease in absorbance at 240 nm.
Measurement of total antioxidant capacity (PAO) of blood
serum
The total antioxidant capacity in serum was performed
by the use of the PAO kit (Nikken SEIL Co., Japan)
according to the manufacturer’s instruction.Measurement of 8-hydroxy-2-deoxy guanosine (8OHdG)
level in blood serum
The level of 8-OHdG in serum was performed by the
use of the 8-OHdG EIA kit (Cayman Chemical, USA)
according to the manufacturer’s instruction.
MtDNA copy number determination
DNA aliquots of 50 ng were subjected to quantitative PCR
using FastStart Universal SYBR Green Master (ROX) kit
(Roche Applied Science, Switzerland) on 7500 Fast Real-
Time PCR System (ABI, USA). Both, DNA fragments of
ND1 gene (mtDNA encoded, 5′GGAGTAATCCAGGT
CGGT, 5′TGGGTACAATGAGGAGTAGG) and β-actin
gene (internal standard, 5′CATGTGCAAGGCCGGCT
TC, 5′CTGGGTCATCTTCTCGCGGT) were amplified
by PCR using the manufacturer’s protocol. The relative
copy number of mtDNA per cell was measured by
normalization of the crossing point between ND1 and
β-actin using the 7500 Fast System software (ABI, USA).
Data analysis
All statistical tests (Chi Squared homogeneity testing,
logistic regression, F test, t test, Odds ratio and Fisher
exact test) were performed with the use of the SPSS stat-
istical package, version 11.5 (SPSS Inc. Released 2002.
SPSS for Windows, Chicago, SPSS Inc.).
Of note, in this study the power of the hypothesis test
for B4a1a (or np 15746) in the T2d group reached 0.57,
and 0.76 in the T2D group with IS. Because T2D is a
multifactor and polygenic disorder, we believe that these
powers were satisfactory for the tests.
Results
MtDNA polymorphism
Participants were separated into four groups according
to their medical history: _Control: Unrelated Healthy
individuals with no previous T2D or ischemic Stroke
(IS) history
T2Donly: T2D patients with previous T2D history, but
no IS history.
T2DIS: T2D patients having previous T2D and IS
histories.
ISonly: Patients with previous IS history but no T2D
history.
Comparison of the mtDNA haplogroup frequencies
between control and disease groups (Table 1) using Chi
Squared homogeneity testing did not shown significant
differences (data not shown). On the other hand, when
testing for haplogroup pairwise differences between
control and disease groups using Fisher exact test, sig-
nificant differences were seen in the T2D groups for
B4c1b2a, D4, E2 (P < 0.01), B4a1a and F4 (P < 0.05), and
Table 1 Relative and absolute () frequencies and mtDNA




Control T2Dall T2Donly T2DIS ISonly
N = 327 N = 373 N = 308 N = 65 N = 108
A 1.83 (6) 2.14 (8) 2.27 (7) 1.54 (1) 2.78 (3)
B4 0.92 (3) 0.54 (2) 0.65 (2) - -
B4a 3.98 (13) 1.61 (6) 1.62 (5) 1.54 (1) -
B4a1a 5.50 (18) 9.12 (34) 7.79 (24) 15.38 (10)* 6.48 (7)
B4a2a 4.59 (15) 1.88 (7) 1.95 (6) 1.54 (1) 3.70 (4)
B4b1a 4.59 (15) 4.29 (16) 4.87 (15) 1.54 (1) 2.78 (3)
B4b1b 0.31 (1) 0.27 (1) 0.32 (1) - -
B4b1c1 0.31 (1) 0.54 (2) 0.65 (2) - -
B4c1b2a 1.22 (4) 4.83 (18)** 4.22 (13)* 7.69 (5)** 1.85 (2)
B4c1b2b 0.61 (2) - - - -
B4c1c 0.61 (2) - - - -
B5 1.22 (4) 0.54 (2) 0.65 (2) - 0.93 (1)
B5a1 2.45 (8) 1.34 (5) 1.30 (4) 1.54 (1) -
B5a2 2.14 (7) 4.29 (16) 4.87 (15) 1.54 (1) -
C 0.61 (2) 1.34 (5) 1.30 (4) 1.54 (1) -
D 0.61 (2) 0.27 (1) 0.32 (1) - -
D4 9.17 (30) 3.49 (13)** 3.25 (10)** 4.62 (3) 10.19 (11)
D5 7.03 (23) 6.17 (23) 6.17 (19) 6.15 (4) 6.48 (7)
E1a 1.22 (4) 2.95 (11) 3.25 (10) 1.54 (1) 2.78 (3)
E1a1a 4.59 (15) 5.09 (19) 5.52 (17) 3.08 (2) 2.78 (3)
E2 0.61 (2) 3.48 (13)** 3.90 (12)** 1.54 (1) 0.93 (1)
F1 0.61 (2) 0.80 (3) 0.65 (2) 1.54 (1) -
F1a 0.92 (3) 0.80 (3) 0.97 (3) - 1.85 (2)
F1a1a 2.45 (8) 1.07 (4) 1.30 (4) - 3.70 (4)
F1a3 2.45 (8) 2.68 (10) 3.25 (10) - 3.70 (4)
F1a4 0.92 (3) 1.34 (5) 1.30 (4) 1.54 (1) 1.85 (2)
F1a5 0.31 (1) - - - 0.93 (1)
F2 1.83 (6) 1.07 (4) 0.97 (3) 1.54 (1) 2.78 (3)
F3 5.20 (17) 6.17 (23) 5.52 (17) 9.23 (6) 4.63 (5)
F4 2.45 (8) 5.63 (21)* 6.17 (19)* 3.08 (2) 5.56 (6)
G 0.31 (1) 0.80 (3) 0.97 (3) - 2.78 (3)*
M 0.92 (3) 0.54 (2) 0.65 (2) - -
M10 0.61 (2) 0.27 (1) 0.32 (1) - -
M12 0.61 (2) 0.54 (2) 0.65 (2) - 0.93 (1)
M33 0.61 (2) 0.27 (1) - 1.54 (1) 0.93 (1)
M7 0.92 (3) 0.80 (3) 0.32 (1) 3.08 (2) -
M7b - 1.07 (4) 0.97 (3) 1.54 (1) -
M7b1 5.50 (18) 2.68 (10) 2.60 (8) 3.08 (2) 8.33 (9)
M7b3 1.83 (6) 1.88 (7) 1.95 (6) 1.54 (1) 1.85 (2)
M7b4 0.31 (1) 0.27 (1) - 1.54 (1) -
M7c 1.22 (4) 0.54 (2) 0.65 (2) - -
M7c1 0.31 (1) 1.34 (5) 1.30 (4) 1.54 (1) 0.93 (1)
Table 1 Relative and absolute () frequencies and mtDNA
haplogroup differences between control and disease
groups (Continued)
M7c2 0.31 (1) 0.27 (1) 0.32 (1) - -
M7c3a 2.75 (9) 3.22 (12) 3.57 (11) 1.54 (1) 0.93 (1)
M7c3b 0.31 (1) 0.27 (1) 0.32 (1) - -
M7c3c 3.36 (11) 4.56 (17) 4.55 (14) 4.62 (3) 6.48 (7)
M8a 2.14 (7) 1.88 (7) 1.95 (6) 1.54 (1) 2.78 (3)
M9a 0.61 (2) - - - 0.93 (1)
N9a 2.75 (9) 2.41 (9) 1.95 (6) 4.62 (3) 3.70 (4)
R9 2.45 (8) 1.61 (6) 1.62 (5) 1.54 (1) 2.78 (3)
Z3 0.92 (3) 1.07 (4) 0.32 (1) 4.62 (3) -
T2Dall _Type 2 Diabetes (T2D) with or without ischemic stroke (IS); T2Donly _T2D
patients without IS; T2DIS _T2D patients with IS; ISonly _IS patients with no T2D.
P value *<0.05, **< 0.01.
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were retained when correcting for multiple test.
Disease association between mtDNA polymorphism and
disease groups
Odds Ratios (OR) obtained from logistic regression ana-
lysis (using adjustment for age, gender, population and
haplogroups) between all groups are shown in Table 2 (left
column). A male gender effect (Table 2 and Additional file 3:
Table S3) showed only in disease groups that included pa-
tients with IS history (T2Dall, T2DIS and ISonly). The
association was most significant in the ISonly group (P <
0.001) where age was also a contributing factor. Interest-
ingly, no mtDNA associations were seen in the ISonly
group. Further, significant associations of haplogroups
B5a2b, E, and E2b1 (P < 0.05) were seen in the T2Donly
group, and of haplogroups B4a1a and B4c1b2 (p < 0.01) in
the T2DIS group. Finally, haplogroup D4 showed protec-
tion against T2D (OR 0.35, 95% CI 0.18 ~ 0.66 P < 0.001).
Odds Ratios analyses with Fisher’s exact test were car-
ried out on a smaller data set of complete sequence of
mtDNA genomes (N = 239) (Table 2, middle column).
Most mtDNA-SNPs showing significance correlated
with results obtained with the logistic regression analysis
(Additional file 4: Table S4: significant mtDNA SNPs
associated with diseases). In each set of significant SNPs
(column 2 or 3, Table 2 and Additional file 4: Table S4),
one SNP was actually a founding position in the mtDNA
phylogeny [13] and correlated to findings previously
identified using logistic regression. For example, nucleotide
positions (nps) 4491, 7598 and 13626 are all key nucleotide
determinants of macro-haplogroup E, and nps 4883 and
5178A are key determinants of macro-haplogroup D.
On the contrary, while haplogroup E2b1 showed sig-
nificance in the logistic regression analysis, nps 3027,
3705, 6620, 10834, 13254, 14577 and 14766 belonged to
Table 2 Significant Odds Ratio (OR, 95% CI) between Control and Disease groups using genders, age and mtDNA polymorphism
Disease groups Explanatoryvariables Logistic regression Fisher Exact test using SNPs between control and disease groups
Gender, age, population and haplogroups
(Control = 327 Desease = 481)
SNP markers from complete sequencing (Control= 73,
T2Dall=103, T2D only=70, T2D IS=33, IS= 63)
SNP markers from partial sequencing
(Control= 327, Disease= 481)
T2D With and without IS (T2Dall)
Gender 0.67, 0.51~0.89** 0.40, 0.21~0.74** 0.61, 0.48~0.78***
Population 1.7, 1.23~2.2*** - 1.7, 1.27~2.31***
B4a1a - 3.93, 1.09~14.12* -
B5a2b - - 2.13, 1.07~4.24*
D 0.53, 0.35~0.82** - 0.42, 0.24~0.74**
D4 0.35, 0.18~0.66*** - -
E1 - - 1.95, 1.04~3.65*
F4b - - 2.56, 1.23~5.34*
T2Donly
Population 1.5, 1.1~2.0** 2.71, 1.37~5.49** 1.86, 1.36~2.55***
B4a1a - 3.83, 1.01~14.54* -
B5a2b 2.95, 1.23~7.05* - 2.38, 1.18~4.79*
D 0.57, 0.37~0.90* - -
D4* 0.36, 0.18~0.72* 0.25, 0.07~0.93* 0.32, 0.17~0.61***
D5/M7 - - 0.57, 0.33~0.98*
E 1.89, 1.15~3.10* 3.64, 1.25~10.64* 1.86, 1.16~2.97**
E1a1 - 2.99, 1.09~8.22* 1.86, 1.16~2.97**
E2b1 4.32, 1.36~13.72* - 1.86, 1.16~2.97**
F4b - - 1.82, 1.03~3.22*
T2D with IS (T2DIS)
Gender 0.52, 0.29~0.91* 0.38, 0.16~0.89* 0.44, 0.28~0.69***
Age 1.06, 1.03~1.08*** nt nt
B4a1a 3.90, 1.70~8.06*** 5.19, 1.21~22.22* 2.34, 1.04~5.30*,
B4c1b2 4.39, 1.50~12.80** - -
Ischemic Stroke (ISonly)
Gender 0.51, 0.32~0.81** 0.29, 0.14~0.58*** 0.48, 0.32~0.71***
age 1.10, 1.08~1.13*** nt nt
F4b - - 3.09, 1.11~8.59*
T2Dall _Type 2 Diabetes (T2D) with or without ischemic stroke (IS); T2Donly _T2D patient without IS; and T2DIS _T2D patient with IS; ISonly _IS patient with no T2D.
SNPs obtained from partial sequencing include HVS1, np 8000 to np 9000 and np 9800 to np 10900 regions.
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branch of E2b1 [13], both branches having in common
nps 4491, 7598 and 13626. Such discrepancies between
columns in Table 2 were most likely due to sub-sampling
when reanalyzing the data using different typing/testing
method.
MtDNA partial sequencing results (Table 2 and
Additional file 4: Table S4, column 3) were also used
as they represented a larger data set (N = 808). It was
expected that all significant SNPs would correlate to a
haplogroup association determined using logistic regres-
sion analysis (B4a1a, B5a2b, D4, and E2b1). As above, few
discrepancies were obtained with the two previous analyses.
While sampling may be the causal factor, parallel mutations
occurring between different haplogroups are commonly
seen within the hypervariable control region of the mtDNA
and could have contributed to the discrepancy.
Of note, haplogroup F4b was significantly associated
with all disease groups when using mtDNA partial
sequencing (Table 2 and Additional file 4: Table S4,
column 3), it was not selected by logistic regression nor
with the complete mtDNA sequencing data set. This
result may also be the result of sampling variation and
should be used with caution or confirmed with a larger
data set.
Functional and physiological measurements
Comparisons of functional and physiological measure-
ments of the control group with all patients in the four
disease groups are shown in Table 3. Lowest levels of
LDL and total cholesterol (Table 3) were seen among
individuals with T2Donly and highest measurements of
systolic blood pressure and triglyceride (TG) were seen
in the T2DIS group. The ISonly group had the lowest TGTable 3 t Test, comparison of physical and functional data be
Physical or functional measurements
Control (±2 SD) T2D
N = 254 N = 2
BMI (kg/m2) 26.1 ± 4.6 26.9 ±
Systolic BP (mmHg) 130 ± 17 143 ±
Diastolic BP (mmHg) 83 ± 12 78 ± 1
HDL (mg/dL) 46 ± 16 38 ± 2
LDL (mg/dL) 127 ± 37 107 ±
Total-Cholesterol: TC (mg/dL) 199 ± 55 174 ±
Triglyceride: TG (mg/dL) 134 ± 131 169 ±
Oxidation damage of DNA: 8OHdG (pg/ml) 4584 ± 1528 5862
Plasma anti-oxidant capacity: PAO (mM) 717 ± 277 746 ±
ATP (fmole/cell) 0.64 ± 0.31 0.67 ±
Hydrogen peroxide production (DCF) 44 ± 38 44 ± 3
Lipid Peroxidation 1.25 ± 1.45 1.07 ±
Mitochondrial membrane potential (DiOC) 15 ± 10 13 ± 9
P value: *< 0.05, **< 0.01,***< 0.001.level and total plasma anti-oxidant capacity (PAO), and
the highest oxidation damage of DNA, as inferred from
high plasma 8OHdG. In general, these results were as
expected from literature review for T2D [14,15].
Pairwise comparisons of physiological and mitochon-
drial functional measurements between control and dis-
ease groups within haplogroups that were determined as
significant in Table 2 (Additional file 5: Table S5) showed
little variation within groups. However when comparing
specific measurements between the disease groups, vari-
ation was noticeable. This suggested that specific mtDNA
haplogroups/haplotypes could affect the outcome of
functional and physiological measurements, and pos-
sibly reflect the health condition of the individuals.
To determine if the mtDNA polymorphism affect the
health status of the individuals, the variances of physio-
logical and functional measurements of the pooled data
set were compared with the data regrouped according to
haplogroups and haplotypes (Figure 1). The complete
mtDNA genomic sequence data set (73 controls, 71
T2Donly, 33 T2DIS and 63 ISonly) was used and stratified
into test specific triplets each containing a subset of the
test regrouped according to haplogroup (red), a subsets
regrouped according to haplotypes (white) and a pool of
the two subsets (blue). In Figure 1, each variance in a trip-
let was divided by the highest variance obtained in that
triplet hence normalizing the data into a zero to one scale
of ratios. It was hypothesized that the variances in each
test specific triplets would show little differences to its
pooled variance if the mitochondrial DNA polymorphism
had no effect on the disease state (i.e. of T2D) of the
individuals. No significant variance changes were seen
for mitochondria copy number, Catalase and anti-oxidant
capacity (PAO). Alternatively, a mitochondrial genetictween control and disease groups
all (±2 SD) T2Donly (±2 SD) T2D IS (±2 SD) ISonly (±2 SD)
71 N = 189 N = 82 N = 132
4.9 27.0 ± 5.0 26.8 ± 4.7 25.0 ± 4.5
26*** 136 ± 22* 158 ± 29*** 153 ± 24***
4** 76 ± 13*** 83 ± 16 85 ± 15
8 36 ± 14*** 42 ± 43 38 ± 14*
52* 98 ± 50*** 123 ± 52 117 ± 43
64*** 170 ± 67*** 185 ± 51 187 ± 127
163 169 ± 174 170 ± 138 120 ± 76
± 2973** 5891 ± 2678** 5799 ± 3566 6894 ± 4555*
254 786 ± 268 669 ± 207 635 ± 218
0.34 0.64 ± 0.32 0.73 ± 0.38 0.80 ± 0.45
8 46 ± 35 40 ± 45 40 ± 42
1.05 1.11 ± 0.98 0.95 ± 1.22 1.73 ± 5.75
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Figure 1 F Test: Normalized variance of measurements between the pooled Data and groups differentiated according to Haplogroups
and Haplotypes. Clinical measurements and their variance (F test).
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ated with a significant amount of variance difference
between the pooled data and the subsets in a triplet.
The higher polymorphism seen in the pooled data
groups of the 11 triplets on the right of Figure 1 showed
higher variance (P < 0.05) than seen in the correspond-
ing haplotype subsets, indicating a mitochondrial gen-
etic effect on the health status. The unexpected patterns
seen with triplets for superoxide dismutase, H2O2 intra-
celular level and body mass index showing a reversed
relationship (with haplotype variance being much larger
than the pooled data) were not expected.
Non-synonymous mutation np 15746 in B4a1a may affect
the health status
MtDNA haplogroup B4a1a is prevalent in Taitung
(southern Taiwan). The mtDNA phylogeny determines this
haplogroup with one control region variation (np 16519)
and three coding region variations (nps 6719, 12239 and
15746). Only transition A15746G corresponds to a change
of Isoleucine (Ile) to Valine (Val) at amino acid position
334 in cytochrome b. This mutation was first reported
in a T2D Japanese individual bearing mtDNA hap-
logroup G (Human Mitochondrial Genome Polymorph-
ism Database, http://mtsnp.tmig.or.jp/mtsnp/index_e.
shtml, NDsq0208). A search of the Phylotree database
[13] also showed the presence of this mutation in hap-
logroup N8. This indicates that the association of np
15746 with T2D may be seen with different haplogroups
in different populations (G3a in Japan, B4a1a1 in Island
Southeast Asia and putatively N8 in South China) [16,17].
Accordingly, we constructed the inferred global structures
of the Cytochrome b protein of B4a1a, G3a, and N8 indi-
vidual using the I-TASSER protein structure prediction
algorithm [18]. Amino acid 334 of Cytochrome b appearedin close proximity to the ubiquinol binding site at amino
acid 278 [19], in the 3D structure (data not shown), and a
force field energy increase from −39 KJ/mole to −7 KJ/
mole [20] suggested reduction of the stability of the Cyto-
chrome b coenzyme Qo pocket (Additional file 6: Table
S6). The potential to affect the protein function of cyto-
chrome b in carriers of variant 15746 was equally con-
firmed using the structure based method I-Mutant v2.0
software [21]. Further, when using the 3D protein struc-
ture prediction modeling program RaptorX [22] for Cyto-
chrome b, the Ile to Val amino acid switch at 334
appeared to affect the highly conserved “PEWY” motif
(Amino Acid position 270–273) within the Qo pocket [19]
with a force field energy change at Amino Acid 273 (Tyr)
increasing from −10 to 725 KJ/mole and again suggesting
reduction of Qo activity (Additional file 6: Table S6).
Finally, a note of caution comes to order as the aver-
age younger age of the control group (Additional file 3:
Table S3) and the high CV of flow cytometry test results
(Additional file 2: Table S2) may influence the outcome
of the statistical tests of this study.
Discussion
Several mtDNA disease association studies have been re-
ported on
i) mtDNA mutations related to maternal inherited
diseases, such as MELAS, LHON, MERRF [23];
ii) mtDNA haplogroup association to disease
occurrence [6-8,24-28]; and
iii) approaches using animal models to study mtDNA
mutations in disease and aging [29,30].
All these studies have ubiquitously agreed on the sig-
nificant importance of the role of the mitochondria on
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tial and complete mtDNA genome sequencing to first
determining which mtDNA haplogroup was associated
with the occurrence of T2D among southern Taiwanese
(Tables 1, 2 and 3), and secondly determine if func-
tional or physiological measurements in T2D probands
showed variation with different mtDNA polymorphism
(Figure 1).
Mitochondrial polymorphism influence physiological and
mitochondrial functional measurements
All tissues except erythrocytes carry mitochondria. Mito-
chondria are the main site of formation of reactive oxy-
gen species (ROS) byproducts in the cells. ROS can
modify the function of many essential signal transduc-
tion pathway components and transcription factors
[31,32]. While having an effect on cells apoptosis it also
has a recruiting effect on platelets and leukocytes to in-
duce the host defense [33]. The relationship mtDNA
polymorphism, ROS and its effect on the general physio-
logical performance is not fully understood. In animal
model, researchers have observed that variation in the
count of mtDNA SNPs was associated with hypertension
[34] and to ROS activity. On the other hand it was ob-
served that suppression or reduction of ROS could be
beneficial to endothelial cell relaxation [35] and could
lower blood pressure. Further, lower efficiency of the
electron transport chain (ETC.) was associated to ROS
induced morbidity, and malfunction of the mitochon-
drion associated with hyperlipidemia [36,37]. In the
current study, only mtDNA haplogroup B4a1a in the
T2DIS group showed significant variation in systolic
blood pressure (Additional file 5: Table S5). This obser-
vation was in agreement with cybrid studies analyzing
mtDNA haplogroup associations with different cellular
biochemical functions [38,39]. The comparisons of variance
(Figure 1) between groups stratified according to pooled
data, haplogroups and haplotypes confirmed these findings
suggesting that groups with lowest mtDNA diversity
(haplotype groups) produced the lowest variance between
functional measurements. This was shown in Figure 1 for
ATP production, lipid peroxidation, DNA oxidation, mito-
chondrial inner membrane potential, lipid metabolism
(LDL, HDL, total cholesterol, and triglyceride) and blood
pressure. In summary, mtDNA variation may influence the
activity of the protein in the mitochondrial electron trans-
port chain complexes (ETC.) which is the major generators
of ROS in cells and tissues.
Nucleotide 15746 of mtDNA haplogroup B4a1a is a risk
factor for T2D in Island Southeast Asia and Oceania
Probands bearers of mtDNA haplogroup B4a1a, a sub-
haplogroup of B4, had higher systolic BP (P < 0.01), DNA
oxidation (8OHdG) levels and lower serum triglyceride.These measurements had large SD when compared with
the control group (Table 3). However, when only select-
ing healthy individuals with haplogroups ancestral to
B4a1a (i.e. individuals with B4, B4a, B4a1), the SD
remained the same as the control group (data not
shown). This suggested that only variant nucleotides np
6719, 12239, 15746 and 16519 that determine the more
recent B4a1a branch in the B4 phylogeny was associated
with T2D.
The A to G transition at np 15746 is the only non-
synonymous mutation on this branch and corresponds
to a change of amino acid 334 in cytochrome b from
isoleucine (Ile) to valine (Val). The same transition
(A15746G) was also observed in one Japanese T2D
patient with mtDNA haplogroup G, and with low
frequency in southern Chinese haplogroup N8. When
using the I-TASSER or Raptor X 3D protein structure
modeling software, valine 334 was located in close
proximity to the coenzyme Q binding site (amino acid
278 of Cytochrome b) and strong force field energy
changes were predicted near or within the Q pocket by
both models. Amino acids 271 (GLU), 273 (TYR) and
278 (TYR) of human Cytochrome b are important in
the ubiquinol oxidation and binding of the Rieske protein
for the electrons transport of complex III [40-42]. The 3D
protein structure models inferred using I-TASSER and
Raptor X 3D algorithms suggested instability and lower
efficiency of Cytochrome_b Qo site function. It is there-
fore plausible that the reactive oxygen species (ROS)
and H+ movements from the mitochondrial matrix to
the intermembrane space may diminish the respiratory
chain enzyme efficiency [41] in B4a1a individuals. Hap-
logroup B4a1a and its derived sub-haplogroups
(B4a1a1, B4a1a1a) are all determined by np 15746, and
are prominent in Island Southeast Asia and Oceania
[3,43-45]. Actually, the occurrence of T2D in ISEA,
Oceania and the Pacific Region is very high (WTO
STEPS Country Reports: American Samoa NCD Risk Fac-
tors; http://www.who.int/chp/steps/Printed_STEPS_Repor-
t_American_Samoa.pdf). It was shown that the prevalence
of T2D in the 55 to 64 years age group in Samoa is 71%.
Also the major causes of death, coronary heart disease,
stroke, high blood pressure and mature onset diabetes
are all associated to obesity (WTO STEPS Country Re-
ports: American Samoa NCD Risk Factors; http://www.
who.int/chp/steps/Printed_STEPS_Report_American_-
Samoa.pdf ). Further the frequency of B4a1a1a in Samoa
in ~80% [43]. This health pattern is surprisingly similar
to the one seen among carriers of haplogroup B4a1a in
our Taitung data set in southern Taiwan and further
support the argument that np 15746 could be a risk fac-
tor associated to T2D occurrence. Of note, SNP 15746
carriers with other mtDNA haplogroup have never been
seen in Taiwan.
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15746 in ISEA, Taiwan and Polynesia may be the result
of an evolutionary advantage such as adaptation to the
hot and humid environment of these regions [46]. It was
recently hypothesized that insulin resistance may render
defender cells more immuno-efficient by having better
access to energy [5]. How an evolutionary survival ad-
vantage can be associated to B4a1a and at the same time
lower the health status of the individual still remains
matter to further studies.
Conclusions
Regardless of age, men seemed generally more suscep-
tible to T2D than women in southern Taiwan. Although
the significant association of B4a1a and E2b1 with T2D
ceased when corrected for multiple test, these haplogroups
are seen only among Taiwan Aborigines, Island Southeast
Asians and Pacific Ocean islanders where T2D is predom-
inant. More over, we showed that specific mtDNA genetic
profiles may produce specific physiological and biochem-
ical measurements outcomes. More understanding of the
function of the mitochondrion and its relation to T2D will
indicate ways to the clinician of influencing the early
course of the disease.
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